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1. Introduction
1.1 Mouth dissolving Drug Delivery System
The  concept  of  Mouth  dissolving  Drug  Delivery  System emerged 
from the desire to provide patient with more conventional means of taking 
their medication. It is difficult for many patients to swallow tablets and hard 
gelatin capsules. Hence they do not comply with prescription, which results 
in high incidence of non - compliance and ineffective therapy. In some cases 
such as motion sickness, sudden episodes of allergic attacks or coughing and 
unavailability  of  water,  swallowing conventional  tablets may be difficult. 
Particularly the difficulty is experienced by paediatric and geriatric patients. 
Such problems can be resolved by means of Mouth Dissolving Tablet. When 
put  on  tongue,  this  tablet  integrates  instantaneously,  releasing  the  drug, 
which dissolves or disperses in the saliva. Some drugs are absorbed from the 
mouth, pharynx and esophagus as the saliva passes down into the stomach. 
In  many  cases,  bioavailability  of  drug  is  significantly  greater  than  those 
observed from conventional tablet dosage form.
The advantages of Mouth Dissolving dosage forms are increasingly 
being recognized in both, industry and academia. Their growing importance 
was underlined secularly when European Pharmacopoeia adopted the term 
"Orodispersible Tablet" as a tablet that to be placed in the mouth where it 
disperses rapidly before flowing.
1.2 Desired Criteria for Mouth Dissolving drug Delivery System
(MDDS) 1, 2, 3
 Mouth dissolving tablet should – not require water to swallow, but it 
should dissolve or disintegrate in the mouth in matter of seconds. 
•  Be compatible with taste masking.
•  Be portable without fragility concern.  Have a pleasing mouth feel.
•  Leave minimal or no residue in the mouth after oral administration.
•  Exhibit low sensitivity to environmental conditions as humidity and 
           Temperature.
•  Allow the manufacture of tablet using conventional processing and 
  Packaging equipment at low cost.
Salient Features of Mouth Dissolving Drug Delivery System2, 4, 6
•  Ease of administration to patients who refuse to swallow a tablet, 
such as paediatric and geriatric patients and , psychiatric patients.
• Convenience of administration and as accurate dosing as compared to 
           Liquids.
•  No  need  of  water  to  swallow  the  dosage  from,  which  is  highly 
convenient  feature  for  patients  who are  traveling  and  do  not  have 
immediate access to water.
• Good mouth feel property of MDDS helps to change the basic view of 
medication as "bitter pill", particularly for paediatric patients.
•  Rapid dissolution of drug and absorption, which may produce rapid 
onset of action.
• Some drugs are absorbed from the mouth, pharynx and esophagus as 
the saliva  passes down into the stomach, such cases bioavailability of 
drugs is increased.
• Ability to provide advantages of liquid medication in the form of solid 
preparation.
• Pregastric absorption can result in improved bioavailability and as a 
result  of  reduced dosage,  improved clinical  performance  through a 
reduction of unwanted effects.
1.3 Techniques for Preparing Mouth Dissolving Tablets
Table No.1
TECHNOLOGY BASIS FOR TECHNOLOGY COMPANY
Zydis
Quicksolv
Lyoc
Flashtab
Orasolv
Durasolv
WOWTAB
Fast Melt
Ziplets
Flash dose
Oraquick
Pharmaburst
Advatab
Frosta
Lyophilization
Lyophilization
Lyophilization
Molding
Molding
Molding
Molding
Molding
Molding
Cottan candy process
Direct compression
Direct compression
Direct compression
Direct compression
R.P. Scherer, Inc.
Janssen
Farmalyoc
Ethypharm
Cima Labs, Inc.
Cima Labs, Inc.
Yamanouchi
Elan Corpl
Eurand
Fuisz tech ltd
A pharmaceutical
Spipharma
Eurand
Akinainc
Freeze Drying1, 4 
A process,  in which water is  sublimated from the product 
after  freezing,  is  called  freeze  drying.  Freeze-dried  forms  offer  more 
rapid dissolution than other available solid products. The lyophilization 
process  imparts  glossy  amorphous  structure  to  the  bulking agent  and 
some times to the drug, thereby enhancing the dissolution characteristics 
of the formulation. However, the use of freeze drying is limited due to 
high cost of the equipment and processing. Other major disadvantages of 
the final  dosage forms include lack of physical resistance in standard 
blister packs. 
A  tablet  that  rapidly  disintegrates  in  aqueous  solution  includes  a 
partially collapsed matrix network that  has been vacuum dried above the 
collapse temperature of the matrix. The matrix is partially dried below the 
equilibrium freezing point of the matrix. Vacuum drying the tablet above its 
collapse temperature instead of freeze drying below its collapse temperature 
provides a process for producing tablets with enhanced structural integrity, 
while rapidly disintegrating in normal amounts of saliva.
Moulding1, 3, 4, 5 
Tablets produced by moulding are solid dispersions. Physical form of 
the drug in the tablets depends whether and to what extent it dissolves in the 
molten  carrier.  The  drug can exist  as  discrete  particles  or  microparticles 
dispersed in the matrix. It can dissolve totally in the molten carrier to form 
solid solution or dissolve partially in the molten carrier and the remaining 
particles stay undissolved and dispersed in the matrix. Disintegration time, 
Drug dissolution rate and Mouth feel will depend on the type of dispersion 
or dissolution.
Moulded tablets disintegrate more rapidly and offer  improved taste 
because the dispersion matrix is in general, made from water soluble sugars. 
Moulded tablets typically do not possess great mechanical strength. Erosion 
and breakage of the moulded tablet often occur during handling and opening 
of blister packs. 
Moulded  tablets  usually  are  prepared  from  soluble  ingredients  by 
compressing a powder mixture previously moistened with solvent (usually 
water  or  ethanol)  'into  mould  plates  to  form  wetted  mass,(compression 
moulding). Recently moulded forms also have been prepared directly from 
the  molten  matrix  in  which  the  drug  'is  dissolved  or  dispersed  (heat 
moulding) or by evaporating the solvent from the suspension at standard 
pressure (no-vacuum lyophilization).
T.makino,  et.  al  have  also  developed  as  compression-moulded 
mixtures  containing  drug  and  combination  of  starches  and  sugars  with 
surfaces that have been wetted with suitable amount of water. The wetted 
mass  is  compression  moulded  and  dried.  Porous  tablets  with  sufficient 
mechanical strength have been obtained.
Mouldability  is  defined  as  the  capacity  of  the  compound  to  get 
moulded  or  compressed  WOW(without  water)  tablet  is  an  intrabuccally 
dissolving  compressed  moulding  comprising  granules  made  with 
saccharides having low and high mould ability. Low mould ability means 
that  the saccharides  show reduced compressibility  by tableting and rapid 
dissolution.  By  contrast  high  molding,  saccharine  show  excellent 
compressibility and slow dissolution. Wowtab can accommodate high doses 
of  multiparticulate  water  soluble  or  insoluble  drug  and  has  adequate 
hardness.
Sublimation1-4, 6
Because  of  low  porosity,  compressed  tablets  composed  of  highly 
water-soluble  excipients  as  tablet  matrix  material  often  do  not  dissolve 
rapidly in the water. Porous tablets that exhibit good mechanical  strength 
and dissolve  quickly  have been developed by Heinemann and Rose,Inert 
solid  ingredients  (e.g.  urea,  urethane,  ammonium  carbonate,  camphor, 
naphthalene)  were  added  to  other  tablet  excipients  and  the  blend  was 
compressed  into  tablet.  Removal  of  volatile  material  by  sublimation 
generated a porous structure.
A method of producing fast dissolving tablet using water as the pore 
forming  material  has  been  described  by  Makino.  Compressed  tablets 
containing  mannitol  and  camphor  have  been  prepared  by  sublimation 
technique. The tablets dissolve within 10-20 seconds and exhibit sufficient 
mechanical  strength  for  practical  use.  Koizumi  have  developed  a  new 
method of preparing high porosity rapidly saliva soluble compressed tablets 
using mannitol with camphor, a subliming material.
Spray-Drying1-4
Highly porous and fine powders can be produced by spray drying, as 
the  processing  solvent  is  evaporated  rapidly  during  spray  drying.  Spray 
drying technique has been employed by Allen and Wang to prepare fast 
dissolving tablets. They developed formulation by using mannitol as bulking 
agent,  hydrolysed  and  non-hydrolysed  gelatin  as  support  matrix,  sodium 
starch glycolate as disintegrant and acidic material (ex. citric acid) and/or 
alkali material (ex.NaHC03) to enhance disintegration and dissolution. When 
immersed in an aqueous medium, the tablets compressed from spray-dried 
powder, disintegrated within 20 seconds.
Mass-Extrusion 1
This technology involves softening the active blend using the solvent 
mixture of water soluble polyethylene glycol, using methanol and expulsion 
of softened mass through the extruder or syringe to get a cylinder of the 
product into even segments using heated blade to form tablets. The dried 
cylinder can also be used to coat granules of bitter tasting drugs and thereby 
masking their bitter taste.
Direct Compression 1, 3,7,8,9
It is the easiest way to manufacture tablets. Conventional equipment, 
commonly available excipients and a limited number of processing steps are 
involved in direct compression. Also high doses can be accommodated and 
final weight of tablet can easily exceed that of other production methods. 
Directly  compressed  tablet's  disintegration  and  solubilization  depends  on 
single  or  combined  action  of  disintegrants,  water  soluble  excipients  and 
effervescent agent. Disintegrant efficacy is strongly affected by tablet size 
and hardness. Large and hard tablets have disintegration time more than that 
usually  required.  As  consequences,  products  with,  optimal  disintegration 
properties often have medium to small size and /or high friability and low 
hardness. Breakage of tablet edges during handling and tablet rupture during 
the  opening  of  blister  alveolus.  All  result  from  insufficient  physical 
resistance.
Disintegrants  have  major  role  in  the  disintegration  and  dissolution 
process of Mouth Dissolving Tablets made by direct compression. To ensure 
a high disintegration rate, choice of suitable type and an optimal amount of 
disintegrant  is  important.  Other  formulation  components  such  as  water 
soluble excipients or effervescent agents can further enhance dissolution or 
disintegration  properties.  But  main  drawback  of  using  effervescent 
excipients is their highly hygroscopic nature.
The  understanding  of  disintegrant  properties  and  their  effect  on 
formulation has advanced during last few years, particularly regarding so 
called  superdisintegrants.  Disintegration  efficiency  is  based  on  force 
equivalent concept, which is the combined measurement of swelling force 
development and amount of water absorption. Force equivalent expresses 
the  capability  of  disintegrant  to  transform absorbed  water  into  swelling 
force. The optimization of tablet disintegration was defined by means of 
disintegrant  critical  concentration.  Below  this  concentration,  the  tablet 
disintegration time is inversely proportional  to disintegrant  concentration 
and above that disintegration time remains approximately constant or even 
increases.
The simultaneous presence of disintegrant with a high swelling force 
called disintegrating agent and substances With low swelling force ( starch, 
cellulose  and  direct  compression  sugar)  define  "swelling  agent"  was 
claimed to be a key factor for rapid disintegration of table, which also offers 
physical-resistance.
Patented Technologies for Mouth Dissolving Tablets 
Zydis Technology 10
Zydis formulation is a unique freeze dried tablet in which drug is 
physically  entrapped  or  dissolved  within  the  matrix  of  fast  dissolving 
cancer materials when zydis units are put into the mouth; the freeze-dried 
structure  disintegrates  instantaneously  and does not  require  water  to  aid 
swallowing. The zydis matrix is composed of many materials designed to 
achieve a number of objectives. To impart strength and resilience during 
handling, polymers such as gelation, dextran or alginates are incorporated. 
These form a glossy amorphous structure, which imparts strength. 
To  obtain  crystallinity,  elegance  and  hardness,  saccharides 
such  as  mannitol  or  sorbitol  are  incorporated.  Water  is  used  in  the 
manufacturing  process  to  ensure  porous  units  to  achieve  rapid 
Disintegration.  Various  gums  are  used  to  prevent   sedimentation  of 
dispersed drug ,particles in the manufacturing process. Collapse protectants 
such as glycine prevent the shrinkage of zydis units during freeze  drying 
process or long term storage. Zydis products are packed in blister packs 
protect the formulation from moisture in environment.
Durasolv Technology11
Durasolv is the patented technology of CIMA labs. The tablets made 
by  this  technology  consist  of  a  drug,  fillers  and  lubricant.  Tablets  are 
prepared by using conventional tableting equipment and have good rigidity. 
These can be packaged into conventional packaging system like blisters. 
Durasolv is an appropriate technology for products requiring low amounts 
of active ingredients.
Orasolv Technology 11
Orasolv Technology has been developed CIMA labs. In this system 
active  medicament  is  taste  masked.  It  also  contains  effervescent 
disintegrating agent. Tablets are made by direct compression technique at 
low  compression  force  in  order  to  minimize  oral  dissolution  time. 
Conventional blenders and tablet machine is used to produce the tablets. 
The  tablets  produced  are  soft  and  friable  and  packaged  in  specially 
designed pick and place system.
Flash Dose Technology12 
Flash dose technology has been patented by Fuisz. Nurofen meltlet, a 
new  form  of  as  melt-in  –  mouth  tablets  prepared  using  flash  does 
technology is the first commercial product launched by Biovail Corporation 
flash does tablets consists of self binding shear form matrices are prepared 
by flash heat processing.
Wowtab Technology12 
Wowtab technology is patented by Yamanouchi Pharmaceutical Co. 
WOW  means  “Without  Water”.  In  this  process,  combination  of  low 
mouldability  saccharides  and  high  mouldability  saccharides  is  used  to 
obtain a rapidly melting strong tablet. The active ingredient is mixed with a 
low  mouldability  saccharine  and  granulated  with  a  high  mouldability 
saccharine and compressed into tablet.
Flashtab Technology 13   
Prographarm  laboratories  has  patented  the  Flashtab  technology. 
Tablets prepared by this system consist of an active ingredient in the form 
of  microcrystals.  Drug  microgranules  may  be  prepared  by  using  the 
conventional  techniques  like  coacervation,  microencapsulation,  and 
extrucion  –  spheronisation.  All  the  processing  utilized  conventional 
tabletting technology.  
1.4 Marketed preparations of Melt – in Mouth Tablets
The Current pharmaceutical market for Mouth Dissolving tablets is 
on increasing trend. Because of  strong patient  demand,  several  products 
have been commercialized. 
Table No. 2
Name of Product Manufacturer & Country Remark
Imodium Lingual R.P. Schere corp. USA Fast Dissolving 
Formulation of Imodium
Pepcidin Rapitab Mktd. By Merck & co., USA Quick  Releasing  ant  ulcer 
preparation of pepcid  
Mosid – MT Torrent  Pharmaceuticals, 
India.
Mouth  melt  tablet  of 
Mosapride citrate.
Calritin Reditabs Mktd.  By  Schering  Plough 
Corp., USA
Immediate  Dissolving 
Formulation citrate.
Nimulid – MD Panacea Biotech, India Mouth Dissolving tablet of 
Nimesulide 
Zyrof Meltab Zydus Cadila, India Melt – In – Mouth tablet of 
Roefecoxib 
Advantages
Ease  of  administration  to  paediatric  and  geriatric  patients  and 
psychiatric patients. Bioavailability of drugs is increased No need of water- 
convenient for travelers Good mouth feel- changes the basis view as “ bitter 
pill”. Particularly of peadiatric. Produce rapid onset of action convenience of 
administration  and  accurate  dosing  as  compared  to  liquids.  Ability  to 
provide advantages of liquid medication in the form of solid preparation.
1.5 INTRODUCTION TO ASTHMA14
Asthama is defined as a chronic inflammatory disorder of the airways 
in  which  many  cells  such  as  mast  cells,  eosinophils,  T-  lymphocytes, 
macrophages, neutrophils and epithelial cells and cellular elements play a 
role.
In  susceptible  individuals  recurrent  episodes  of  wheezing, 
breathlessness, chest tightedness and coughing. These symptoms are usually 
associated with airflow obstruction. The inflammation causes an increase in 
bronchial hyper responsiveness (BHR) to a variety of stimuli.
The  major  characteristic  of  asthma  includes  a  variable  degree  of 
airflow obstruction (related to bronchospasm,  edema,  and hypersecretion) 
BHR and air way inflammation.
Up to 150 million  people suffer  from asthma in the world and the 
number  has  been  rising  steadily.  The  condition  proves  fatal  for  around 
1,80,000 of the world's population every year. In India, there are about 20 
million asthmatics among which 15 % are children aged between 5 to 11 
years, having symptoms.
Asthma attacks caused by both unknown and known factors such as 
exposure  to  allergens,  viruses,  pollutants  which  may  induce  anti-
inflammatory response.
Inhaled  allergens  causes  an  early  phase  allergic  reaction  due  to 
activation of cells bearing allergen-specific IgE antibodies. There is a
rapid activation of airway mast cells and macrophages, which release anti-
inflammatory mediators such as histamine that induces
 Contraction of airway smooth muscle
 Mucus secretion
 Vasodilatation
 Exudation of plasma in the airways
 Plasma protein leakage induces a thickened, engorged, edematous air 
way leading to a narrowing of airway lumen reducing mucus clearance.
The late phase inflammatory reactions occurs 6 to 9 hrs after allergen 
provocation  and involves  recruitment  and activation  of   eosinophils,  T  - 
lymphocytes, basophils, macrophages and neutrophils.
Mast cells degeneration in response to allergens result in increase of 
mediators such as histamine, eosinophil and neutrophil chemo tactic factors 
leukotrienes  C4,  D4  and  E4  induces  smooth  muscle  constriction  and 
bronchospasm results in mucosal edema and mucus secretion.
Alveolar macrophages releases inflammatory mediators including PAF 
(Platelet  Activating  Factor)  and  leukotrienes  B4,  C4  and  D4.  They  are 
important pre inflammatory mediators in asthma which are derived from the 
metabolism  of  membrane  phospholipids  within  alveolar  macrophages, 
eosinophils, mast cells and neutrophils. Leukotrienes interact with specific 
receptors  found  in  various  tissues  including  the  lung.  Administration  of 
leukotriene  solution  or  aerosol  to  the  airways  mimic  many  of  the 
inflammatory symptoms of asthma including
 Bronchoconstriction
 Increased micro vascular permeability (EDEMA) 
 Leukocyte activation
 Eosinophilia
 Enhanced mucus secretion
Leukotrienes  are  formed  when  the  enzyme  5-lipooxygenase  in 
conjunction  with  cofactor  5-lipooxygenase  activating  protein  metabolizes 
Arachidonic acid. I t is further converted to Cysteinyl leukotrienes such as 
LTC4,  LTD4  are  highly  potent  inducers  of  airway  smooth  muscle 
contraction and bronchoconstriction.
DRUG TREATMENT IN ASTHMA15
The drug treatment of asthma has remained essentially unchanged over 
the past three decades in terms of the use of corticosteroid, β2 agonist, and 
theophylline  drugs.  Asthma  treatment  has  also  been  improved  by  the 
widespread  dissemination  and  implementation  of  management  guidelines 
emphasizing  the  pivotal  role  of  first  line  preventative,  anti-inflammatory 
therapy.
Summary points16
The  dose  of  inhaled  steroid  should  be  titrated  against  asthmatic 
symptoms,  peak flow, and usage of β2 agonist drugs.  The safest  dose of 
inhaled steroid is the lowest effective maintenance dose producing optimal 
long term control and quality of life.
Adding second line anti-inflammatory controller treatment  such as a 
leukotriene  antagonist  or  theophylline  may  be  an  alternative  to 
immunotherapy with a high dose of inhaled steroid.
 If control is inadequate despite optimized anti-inflammatory treatment, 
it is better to add regular treatment with a long acting β2 agonist drug than a 
short acting one.
First principles of treatment
The past decade of research has led to a greater understanding of the 
pathophysiology  of  asthma  and,  in  particular,  the  pivotal  role  of  the 
underlying inflammatory  process.  Current  asthma management  guidelines 
stress the importance of switching off the inflammatory process at the top of 
the  cascade  by  giving  first  line  preventive  treatment  with  inhaled 
corticosteroids,  thereby  reducing  the  need  to  provide  symptomatic  relief 
with short acting β2 agonists at the bottom of the cascade. Drugs such as 
long acting inhaled β2 agonists, theophyllines and anti-leukotrienes may also 
be  used  as  second  line  "controller  treatment"  when  given  with  inhaled 
corticosteroids to improve symptom control and reduce diurnal variability. 
These treatment options should be used conjunction with removal of any 
potential trigger factors.
Common reasons for poor response to treatment
Poor compliance-for example, as a result of having to take drugs (such 
as cromoglycate) four times daily, or polypharmacy Poor technique in using 
an inhaler-for example, difficulty with metered dose inhalers. Presence of 
trigger  factors-for  example,  allergen,  smoking,  occupation,  oesophageal 
reflux,  rhinitis.  Wrong  diagnosisfor  example,  having  chronic  obstructive 
pulmonary disease, bronchiectasis or heart failure rather than asthma.
Goals
A number of optimal treatment goals should be set for a given patient 
within  the  pharmacoeconomic  constraints  of  the  available  health  service 
provision.
Goals of treatment
To achieve normal percentage predicted values for forced expiratory 
volume in one second/peak expiratory flow Reduce diurnal  variability  of 
peak expiratory flow and symptoms
 Minimize use of reliever β2 agonist drugs
 Optimize quality of life
 Reduce risk of severe exacerbation of asthma
Corticosteroids
Inhaled corticosteroids are the most  potent anti-inflammatory agents 
for treating asthma and act in a relatively non-specific manner by inhibiting 
a  variety  of  inflammatory  cells,  cytokine  expression,  and  transcription 
factors which are involved in the inflammatory disease process. The delivery 
directly  to  the  airway  of  relatively  small  doses  of  topically  active 
corticosteroid,  along  with  an  extensive  degree  of  hepatic  first  pass 
inactivation of the swallowed moiety, results in a high therapeutic index-the 
ratio  of  anti-asthmatic  efficacy  to  systemic  adverse  effects.  The  inhaled 
corticosteroid drugs are also the most cost effective form of treatment for. 
preventing asthma.
Dose response relation exact  point  depends on disease  severity  and 
individual sensitivity. Because respirable lung dose improves greatly with 
the hydrofluoroalkane formulation of beclomethasone, half the dose of the 
chlorofluorocarbon formulation can be given, and it to target delivery to the 
inflamed small airways.
Regimen17
The  modern  management  of  persistent  asthma  with 
inhaledcorticosteroid drugs involves starting treatment with a relatively high 
dose for four to eight weeks in order to gain rapid optimal control. This is 
followed by a gradual tapering of the dose to determine the lowest effective 
maintenance  dose  for  a  given person.  For  people  with  mild  to  moderate 
asthma, effective control can usually be achieved by a once daily regimen 
when the patient has been stabilized on maintenance treatment at doses of up 
to 800/mcg/day of budesonide or beclomethasone. Evidence also suggests 
that  early intervention with inhaled corticosteroid drugs may prevent any 
long term decline in lung function resulting from bronchial fibrosis caused 
by untreated chronic inflammation 
Available  data  suggest  that  the  beneficial  effects  of  inhaled 
corticosteroids  on  disease  control  will  outweigh  any  potential  systemic 
bioactivity in terms of long term growth in asthmatic children. No effect of 
these drugs on the final achieved adult height has been shown. Indeed, other 
factors such as socioeconomic status and, perhaps, nutrition may be more 
important  in  determining  height  in  asthmatic  children  taking  inhaled 
corticosteroids Corticosteroid induced osteoporosis may be reduced by the 
use of oestrogen replacement therapy or biphosphonate drugs18.
Long  term  treatment  with  high  doses  of  inhaled  corticosteroids  is 
associated with an increased risk of a posterior sub capsular cataracts and, to 
a lesser degree, with ocular hypertension19. Skin bruising, an adverse effect 
of  inhaled  corticosteroids,  is  more  prevalent  in  elderly  people  and  is 
associated  with  adrenal  suppression20. Indeed,  skin  bruising  is  visible 
evidence of increased collagen turnover, and should therefore prompt further 
screening  for  other  tissue  specific  adverse  effects.  It  may  therefore  be 
prudent  to  perform  a  regular  annual  or  biennial  check  up  to  look  for 
evidence of systemic bioactivity in the skin, eye, adrenal gland, and bone in 
adults  receiving  long  term,  high  dose  inhaled  corticosteroid  treatment 
(>800µlg  daily  of  beclomethasone  or  budesonide  and  >400µlg daily  of 
fluticasone),  and  to  monitor  growth  in  children  (>400µlg  daily 
beclomethasone or budesonide and >200µg daily fluticasone).
Local adverse effects
Local adverse effects  such as oral  candidiasis  may be alleviated by 
using  a  large  volume  spacer  to  reduce  the  deposition  of  drug  on  the 
oropharynx. The occurrence of oral candidiasis is related to the dose and to 
the mucosal exposure time to topical corticosteroid. Thus, a once or twice 
daily dosing regimen will  reduce the likelihood, and this can be reduced 
further  by  regular  mouth  rinsing.  Using  a  spacer  device  has  other 
advantages-there  is  increased  delivery  of  respirable  particles  and  the 
coordination  problems  associated  with  using  metered  dose  inhalers  are 
reduced.
Leukotriene antagonists
The  cysteinyl  leukotrienes  are  metabolites  of  arachidonic  acid 
comprising leukotrienes C4, D4, and E4. The cysteinyl leukotrienes cause 
smooth muscle constriction and proliferation and are important mediators in 
the  pathophysiology  of  the  inflammatory  process.  The  leukotriene 
antagonists such as zafirlukast (twice daily) and montelukast (once daily) are 
well tolerated, seem effective over a wide spectrum of disease severity, and 
exhibit both bronchodilator and antiinflammatory activity21. Responsiveness 
to leukotriene antagonists varies and may be genetically determined by the 
degree of leukotriene synthesis resulting from 5-lipoxygenase activity. In the 
United Kingdom, montelukast is licensed in patients aged 6 years and over 
as  second  line  asthma  controller  treatment  in  combination  with  inhaled 
corticosteroids.  It  is  only  licensed  as  monotherapy  in  the  prophylaxis  of 
exercise  induced  asthma.  Zafirlukast,  however,  is  currently  licensed  in 
patients aged 12 years and over, including first line use instead of inhaled 
corticosteroids22.
Advantages 
One of the main advantages of the leukotriene antagonist drugs is that 
they are active orally, which avoids the potential compliance problems with 
the inhaled route. The compliance factor with leukotriene antagonists may 
also be reinforced by the fact that they work within the first 24 hours, while 
inhaled corticosteroids take much longer to achieve maximal response. The 
leukotriene antagonists are comparable in cost with long acting β2 agonists, 
but are much more expensive than low dose inhaled corticosteroids.
Additive effects
Preliminary data with montelukast  and zafirlukast  suggest  that  they 
show additive effects to low or high dose inhaled corticosteroids22. In multi 
centre studies, montelukast in children (5mg  once daily) or adults (10mg 
once daily) was better than placebo at controlling asthma over eight to 12 
weeks,  and this  effect  was  seen  equally  in  patients  taking  or  not  taking 
corticosteroid25. In addition, montelukast and placebo showed no differences 
in adverse effects  on  biochemical  liver  function tests.  Regular  treatment 
with  montelukast  produces  a  sustained,  high  level  of  protection  against 
exercise  induced  bronchoconstriction,  in  contrast  with  salmeterol,  which 
induces tolerance. 26 Another potential advantage of leukotriene antagonist 
drugs is that  they are effective in treating coexistent  allergic rhinitis33,  A 
Churg-Strauss-like  syndrome  has  been  reported  with  zafirlukast  and 
montelukast;  this  is  probably  due  to  an  unmasking  of  the  underlying 
condition  caused  by  tapering  of  concomitant  oral  corticosteroids,  and 
reinforces that  leukotriene antagonists  should not  be used instead of oral 
corticosteroids in dependent patients with severe asthma.
Need for further data
Thus,  there  seem  to  be  logical  reasons  for  using  leukotriene 
antagonists  as  second  line  controller  treatment  in  that  they  possess  both 
anti–inflammatory  and  bronchodilator  activity,  afford  bronchoprotection 
against  allergen and exercise,  do  not  exhibit  tachyphylaxis,  and are  well 
tolerated  Bronchial  biopsy  studies  show  anti-inflammatory  effects  of 
leukotriene antagonists in reducing numbers of T lymphocytes, mast cells, 
and eosinophils27. However, further efficacy and safety data from long term 
studies  are  needed  to  establish  the  appropriate  place  of  leukotriene 
antagonists in asthma treatment guidelines-in particular, whether they should 
be  used  as  an  alternative  to  low dose  inhaled  corticosteroid  as  first  line 
monotherapy in patients with mild to moderate persistent asthma
Cromones
The cromones include sodium cromoglycate and sodium nedocromil, 
which act  predominantly  by  stabilising  mast  cells.  These  drugs  are  well 
tolerated and have no systemic adverse effects, but they are less effective in 
treating asthma than inhaled corticosteroids. The cromones tend to be most 
effective in patients with mild atopic asthma, particularly in children with an 
exercise or allergen induced component to their condition. However, there is 
uncertainty about the degree of anti-inflammatory activity of the cromones, 
at  least  on  the  basis  of  bronchial  biopsy  studies.  Compliance  may  be  a 
problem with these drugs as they are short acting and need to be taken four 
times daily. Cromone treatment is also much more expensive than that with 
low dose inhaled corticosteroid drugs.
Antihistamines
Cetirizine  and  loratidine  are  examples  of  potent,  selective,  type  I 
histamine receptor antagonists that are well tolerated and are taken on a once 
daily basis. They have a limited role in treating asthma in patients with a 
known allergenic trigger factor such as pollen or animal fur. They may also 
be  of  value  where  there  is  associated  seasonal  allergic  rhinitis  and 
conjunctivitis  or  if  there  is  associated  allergic  urticaria.  Preliminary  data 
suggest that antihistamines and leukotriene antagonists may show additive 
effects  on control  in asthma and allergic rhinitis25.  Antihistamines  should 
never be used as monotherapy for chronic asthma, but only as an adjunct to 
inhaled corticosteroids.
Theophyllines
The bronchodilator activity of oral theophylline is relatively weak and 
high doses are needed. Lower doses of theophylline show anti-inflammatory 
effects, and this finding led to a reappraisal of theophylline's role as second 
line  controller  treatment  in  addition  to  inhaled  corticosteroids.  The 
advantages of theophylline are that it may be taken once or twice daily as an 
oral slow release formulation and is inexpensive.
The main disadvantages of theophylline are several important potential 
drug interactions that may result in drug toxicity as well as the expense and 
inconvenience of therapeutic drug monitoring. Although the adverse effects 
of theophylline are related to the plasma  concentration, the drug tends to be 
less well tolerated, even at low doses, than other second line controller drugs 
such as leukotriene antagonists or long acting β2 agonists
β2 agonists
The β2 agonist drugs act primarily on airway smooth muscle and are 
the most effective form of bronchodilator treatment. Their effects on smooth 
muscle  and  mast  cells  result  in  protection  against  several  stimuli  of 
bronchoconstriction. For example, inhaled β2 agonists are highly effective at 
preventing  bronchoconstriction  when  used  shortly  before  exercise  or 
exposure to known allergens.  Evidence suggests  that regular use of short 
acting  β2  agonists  may  worsen  control  of  asthma,  although  this  claim 
remains contraversies. The requirement for regular use of reliever treatment 
with short acting β2 agonists marks an activated inflammatory cascade and 
hence the need to step up the dose of inhaled corticosteroid 
Long acting β2 agonists
The  long  acting  β2  agonists  salmetrol  and  eformoterol  became 
available against this background of recommending short acting β2 agonists 
for  occasional  use  as  a  reliever.  These  drugs  are  now  included  in  the 
guidelines for regular.  Twice daily use as second line controller treatment in 
conjunction with a low dose of inhaled corticosteroid. This recommendation 
is based on studies which showed that adding a long acting ß2 agonist to a 
low does  of  inhaled  corticosteroid  drug  produced  comparable  control  to 
immunotherapy with a higher dose of inhaled corticosteroid.
Concerns
There is concern that the regular use of long acting ß2 agonists may 
simply palliate the squealae of an activated inflammatory cascade without 
suppressing the underlying process, particularly as ß2 agonists have no anti-
inflammatory  activity.  None  the  less,  long  acting  ß2  agonists  may  be 
valuable  when  given  regularly  for  persistent  symptoms  in  patients  who 
would otherwise need to use short acting ß2 agonists frequently, provided 
adequate anti – inflammatory treatment is also being taken.
We  also  know  that  tolerance  to  the  airway  effects  of  ß2  agonists 
develops when these drugs are regularly and that this is more pronounced for 
loss of bronchoprotective activity than bronchodilator activity27,28. Moreover, 
the  development  of  tolerance  with  long  acting  ß2  agonists  occurs  in 
genetically  predisposed  people.  They  have  a  particular  variant  of  the  ß2 
adrenoceptor,  which occurs  in  up  to  50% of  white  people  in  the  United 
Kingdom.  This  genetic  polymorphism of  the  ß2  adrenoceptor   may  also 
explain  individual  variation  in  the   clinical  response  to  long  acting  ß2 
agonist treatment. Eformoterol is a more potent drug and has a faster onset 
of action than salmeterol. It may therefore be used as required for reliever 
treatment up to the maximum recommended twice daily dose. This type of 
"as  required"   dosing  regimen  with  eformoterol  is  not  recommended  in 
current  asthma  guidelines.  Nor,  however,  does  it  seem  appropriate  to 
advocate  its regular use in every case, particularly if it is not needed all the 
time. New fixed dose combinations of fluticasone and salmeterol will soon 
become available in the United Kingdom26. Although they might improve 
compliance, such formulations are less flexible and may inadvertently result 
in  patients  taking  unnecessary  long  term  treatment  with  long  acting  ß2 
agonists.
Controlled release oral  salbutamol  or  oral  bambuterol  (a prodrug of 
terbutaline)  may,  like long acting ß2 agonists,  be used to treat  nocturnal 
symptoms.  Although  the  oral  formulations  tend  to  be  associated  with 
systemic  effects  such  as  tremor  and  tachycardia,  these  usually  wear  off 
because  of  tolerance.  None  the  less,  drugs  such  as  bambuterol  are  less 
expensive  than  long  acting  ß2  agonists  and,  like  theophylline,  have  the 
advantage of being taken as a once daily tablet.
 Conclusions for drug treatment in Asthma
Inhaled corticosteroids should be used as early as possible as first 
line anti-inflammatory treatment for patients presenting with  symptoms of 
persistent asthma. For patients who have mild to   moderate asthma, there is 
no proved therapeutic benefit in using more potent and expensive drugs such 
as  fluticasone  propionate  than  older  and  cheaper  drugs  such  as 
beclomethasone  dipropionate.  The  therapeutic  index  for  inhaled 
corticosteroids  can  be  optimised  by  tapering  the  dose  until  the  lowest 
effective maintenance dose is achieved and by using a metered dose inhaler 
with  a  spacer  device.  Second  line  anti-inflammatory  controller  treatment 
may be added as an alternative to monotherapy with a high dose of inhaled 
corticosteroid in order to avoid any local and systemic adverse effects with 
the latter treatment. In this respect, there seems to be a rationale for adding 
treatment  with leukotriene antagonists  such as montelukast  or zafirlukast. 
These have anti-inflammatory and bronchodilator properties, do not induce 
tolerance, and can be taken as a once or twice daily tablet. Further long term 
studies are required to evaluate the position of leukotriene antagonists  as 
first line preventer treatment instead of low dose inhaled corticosteroid drugs 
in  patients  with  mild  to  moderate  asthma.  Theophylline  is  a  cheaper 
alternative for second line combined anti-inflammatory treatment, but has a 
lower  therapeutic  index that  requires  drug monitoring  and shows several 
important  potential  drug interactions.  If  asthma control  is  inadequate and 
reliever  drugs  need  to  be  taken  frequently,  despite  optimized  anti-
inflammatory treatment,  regular treatment with long acting β2 agonists is 
preferred to that with short acting β2 agonists.
2. Need for the Present Study
Asthma is a chronic Inflammatory disease, which includes bronchial 
hyper activity and bronchospasm characterized by hyper responsiveness  of 
trachiobroncial smooth muscle to variety of stimuli resulting  in narrowing 
of air tubes, often accompanied by increased secretions and mucosal edema 
resulting in breathlessness (or) dyspnea wheezing cough, chest congestion 
and anxiety about being unable to breathe.
Asthma affects over 5-10% of population in industrialized countries. 
It affects 53 million people across world mostly in United States, France, 
Germany, Italy, Spain, United Kingdom and Japan. More than 400 people 
die every year in India as result of complication arising from serials asthma 
attacks  through  therefore  several  recommendations  and  treatment  being 
reported. 
The treatment of asthmatic symptoms generally includes conventional 
oral dosage like tablets, capsules, oral liquids etc inhalation therapy includes 
metered oral dose inhalers with (or) without spacers, dry powder inhalers 
and  other  aerosol  systems  an  attempt  was  made  for  preparation  of  fast 
dissolving tablets at model bronchodilator, salbutamal sulphate with an aim 
of  reducing  the  lag  time  and  providing  faster  onset  of  action  to  relieve 
immediately acute asthmatic attack..
Disadvantage of other formulation 
1. Conventional solid oral dosage forms longer lag time and slower onset 
of action. 
2. Oral  liquids  provides  faster  onset  of  action  but  require  careful 
handling.
3. Aerosol  systems  are  specific  but  fail  to  deliver  the  actual  dose 
deposited in oropharynz and swallowed.
4. Dry  powder  inhalers  cause  clogging  of  device  and  require  skilful 
operation.
Advantages of MDDS
A fast dissolving tablet form would thus be advantage as salbutamol is 
water soluble and preparation into dissolve rapidly and there by result  in 
rapid absorption without any lag time.
3. LITERATURE REVIEW
Yoshiteru.W et.al., 30 Investigated new method of preparing high porosity 
rapidly saliva soluble compressed tablets of meclizine using mannitol with 
camphor, a subliming material by direct compression method showed that 
tablets  prepared by this  technique   have porosity  and disintegration time 
with in 15 seconds in saliva.
Biyx  et.al., 31 Carried  out  formulation  studies  for  ethenzamide  rapid 
disintegrating table containing micro crystalline cellulose, tabellettose and 
Ac-Di-sol.   Tablet  was  prepared  by  direct  compression  technique  and 
Evaluated. Rapid disintegrating tablet with durable structure and desirable 
taste could be prepared with in the obtained optimum region. 
Shirwaikar A.A.et.al., 32 Formulates atenolol fast disintegrating tablet using 
three  superdisintergrants  croscarmellose  (Ac-di-  sol)  crospovidone 
(Polyplasdone) and sodium starch glycoside. Ac- di- sol proved to be best 
among three and showed satisfactory results.
Yoshutenu .W et .al., 33   Prepared rapid disintegrating tablet in saliva in the 
mouth  by  direct  compression  using  micro  crystalline  cellulose,  low, 
substituted hydroxyl propyl cellulose showed rapid disintegration within 30 
seconds was obtained in vitro using compounding ratios at micro crystalline 
cellulose to low substitute hydroxyl propylcellulose.
Mishra  D.N  et.al.37 Formulate  Fast  dissolving  delivery  system  for 
valdecoxib”. A non- steroidal anti inflammatory drug with valdecoxib and 
anti  inflammatory  properties  using various super  disintegrating agents  by 
direct compression technique and sharing enhanced dissolution.
A Jinichi fukami  et. al., 39 Rapidly disintegration table in the oralcavity 
was prepared using a glycine as a disintegrant. Wetting time prepared from 
carbox methyl cellulose (Ns – 300) having hardness of 4 kg was 35. Tablet 
containing  (Ns-300)  should  the  fastest  disintegration  compared  to  other 
formulation. it was suggested that the tablet formulation contains Ns- 300 
and  glycine  was  highly  applicable  to  water  insoluble  drug  such  as 
ethenzamide.
Masaaki sugimoto et. al., 40 Investigate the effects of crystalline transition 
of  amorphous  sucrose  in  granules  on  the  character  of  resultant  tablets. 
Prepared  by  this  crystalline  transition  method.  We conclude  that  rapidly 
disintegrating oral tablets can effectively be manufactured by the CT method 
using the granules obtained by fluidized bed granulation method.
Madgulkar A.R et. al., 41 found that ion Exchange resin like Indion 414, 
and amberliteIRP88 as super disintegrates useful in the preparation of mouth 
dissolving Delivery system. Indion 414 was found to be better disintegrants. 
Bi-y  Sunda  et.al., 31  He  made  compressed  tablet  which  can  rapidly 
disintegrate  in  the  oral  cavity.   Micro  crystalline  cellulose  and  low 
substituted hydroxy propyl cellulose were used as disintegrates.  it  Shows 
good correlation between the disintegration behaviors in vitro and in me oral 
cavity was recognized.  
Fausett  H, et.  al., 34  Develop  a  rapidly  disintegrating  calcium carbonate 
tablet  by direct  compression and compare it  with commercially  available 
calcium tablets. He used cal – carb 4450, cal - carb 4457, and cal – carb 
4450, can – carb 4457, and cal – carb 4462 tablets were in the range of 7.2 to 
7.7 kg. The D.T was 4.1, 2.1 & 1.9 minutes. This study clearly shows the 
quick  disintegrating  cc  tablets  can  be  formulated  without  expensive 
effervescence technology.
Zhao N, Augusburger LL et. al., 35 To investigate the Influence of swelling 
capacity of super disintegrates in different pH media on the dissolution    of 
hydro – chlorothizide from directly compressed tablets. The reduced uptake 
and swelling capacity of  disintegrates containing ionisable substituents  in 
acidic medium can potentially jeopardize their efficiency in promoting tablet 
disintegration and the drug dissolution rate.
 Reddy  L.H  et.  al., 36 Frames  design  for  fast  dissolving  tablets  for 
promethazine  theoclate.  Tablets  were  prepared  by  effervescent  melt, 
superdisintegrant  addition  and  superdisintegrant  shows  released  character 
was optimal 
.
Mishra D.N et. al., 37  Prepared rapidly disintegrating tablets of meloxicam 
meloxicum is an effective and selective cyclo- oxygenase cox- 2 inhibitor 
with anti-Inflammatory and analgesic properly tablets were prepared with 3 
super  disintegrants  e.g.:  sodium  starch  glycolate,Ac-Di-Sol  and  low 
molecular weight hydroxy propyl methyl cellulose. It was conduced that the 
rapidly disintegrating tablets proper hardness rapidly disintegrating in the 
oral  cavity  with  enhanced  dissolution  can  be  made  using  selected  super 
disintergrants.
Shishu  et.  al., 38 aimed  at  preparing  taste  masked  granules,  rapidly 
disintegrating tablets of chlorphenmiramine maleate, a bitter drug. The taste 
masked  granules  using eudragit  E-100 by me extrusion method.  Directly 
compressed  into  tablets  using  sodium  starch  glycolate  as  a  super 
disintegrants. Successful formulation of oral fast disintegrating tablets which 
had good taste and disintegrated in the oral cavity with in 30s.
Bi. Y – yonezwa., 33 He made tablets prepared by compressing wet granules 
under low compression  force and they drying the resulting wet mass in a 
circulating – air oven. Lactose with various particle sizes was used as the 
excipient. By optimizing compression force, size of the lactose particles, and 
the moisture content of the granules tablets meeting tensile strength greater 
that 0.5 mpa and disintegration time shorter than 15 seconds were obtained 
by the wet compression method
4. AIM AND OBJECTIVE OF WORK
Aim: 
The aim of the present was study to formulate the mouth dissolving 
tablets using super disintegrants and evaluating for its characteristics.
The objective of present study 
1.  To enhance the solubility of salbutamal sulphate by using 
superdisintegrants in the oral cavity.
2. To  develop  mouth  dissolving  drug  delivery  system  and 
enhance the patient compliance. 
This mouth dissolving tablet of salbutamol will disintegrate rapidly in 
the patient mouth without need of water (or) chewing and release its content 
instaneously.
So, this dosage form is more comfortable for pediatric, geriatric and 
psychotic patients.
A  fast  dissolving  tablet  form  would  thus  be  advantage  as  water-
soluble and preparation into dissolve rapidly and there by result  in rapid 
absorption without any lag time.
5. Plan of work
The scheme of proposed work is as follows 
1) Preformulation.
UV Analysis
IR Studies
2) Selection of Excipients
3) Drug-excipient compatibility studies
4) Selection of suitable granulation method.
5) Compression of tablets
6) Evaluation of physical and chemical parameters.
7) Evaluation of tablets.
Evaluation
1) Weight variation.
2) Hardness
3) Friability
4) Disintegration time
5) Dissolution study.
6) Uniformity of content
7) Wetting time
                    8) Stability studies
6. Drug and Excipients
6.1 DRUG   PROFILE43,44,45,46
Drug Name -Salbutamol sulphate
Classification -β2  adrenergic agonist
Synonym -Albuterol sulphate
Chemical structure
  H2SO4
 Chemical Name - α1-[(tert-butylamino) methyl]-4-hydroxy-m-
xylene-                                            α,α'-diol sulfate
 Molecular weight  - 576.71
 Molecular formula - (C13H21NO3)2  H2SO4
 Description
Colour -White to almost white powder
Odour -Odourless
Solubility -Soluble in four parts of water 
                 Slightly soluble in 96% ethanol
Melting point -155ºC 
Optical rotation -Racemic mixture
Mechanism of action 
Albuterol is a moderately selective β2  -adrenergic agonist that 
stimulates  receptors  of  the  smooth  muscle  in  the  lungs,  uterus,  and 
vasculature  supplying  skeletal  muscle.  Albuterol  is  racemic  beta-agonist, 
comprised of an equal mixture of R- and S-isomers. The R-isomer, known as 
levalbuterol,  is  primarily  responsible  for  bronchodilation.  Although  not 
confirmed  during  clinical  trials,  the  S-isomer  of  albuterol  has 
bronchoconstrictive properties inanimalmodels.Intracellularly; the actions of 
albuterol  are  mediated  by  cyclic  AMP,  the  production  of  which  is 
augmented by β2-stimulation.  Albuterol  is  believed to work by activating 
adenylate cyclase, the enzyme responsible for generating cyclic AMP, an 
intracellular  mediator.  Increased  cyclic  AMP  leads  to  activation  of 
proteinkinase  A,  which  inhibits  phosphorylation  of  myosin  and  lowers 
intracellular  ionic calcium concentrations,  resulting in relaxation. The net 
result  of  β2-receptor  agonist  in  the  lungs  is  relaxation  of  bronchial  and 
tracheal  smooth  muscles,  which  in  turn  relieves  bronchospasm,  reduces 
airway resistance, facilitates mucous drainage, and increases vitalcapacity.
                  Albuterol can also inhibit the degranulation and subsequent  
release  of  inflammatory  autocoids  from  mast  cells.  Stimulation  of  β2-
receptors on peripheral vascular smooth muscle can cause vasodilation and a 
modest  decrease  in  diastolic  blood  pressure.  Albuterol  is  an  effective 
adjunctive treatment for hyperkalemia; β2-adrenergic stimulation results in 
intracellular  accumulation  of  serum potassium  due  to  stimulation  of  the 
Na/K ATPase pump, leading to moderate degrees of hypokalemia.
Pharmacokinetics
             Albuterol can be administered as oral tablets or oral solution, but is 
more commonly administered by oral inhalation. Following oral inhalation, 
albuterol  is  absorbed  over  several  hours  from the  respiratory  tract.  It  is 
postulated from studies with other inhaled bronchodilators that most of an 
albuterol  inhaled  dose  (approximately  90%)  is  actually  swallowed  and 
absorbed through the GI tract. Onset of bronchodilation occurs within 5—15 
minutes after oral inhalation, peaks in 0.5—2 hours, and lasts 2—6 hours. 
Administration  via  nebulization does  not  appear  to  significantly  alter  the 
pharmacokinetics of albuterol. When administered orally, albuterol is well 
absorbed through the GI tract.  Onset  of action begins within 30 minutes, 
peak levels are reached in 2—3 hours, and duration of action is 4—6 hours 
for the conventional-release tablets and 8—12 hours for the sustained release 
product.
             Albuterol crosses the blood-brain barrier and may cross the placenta. 
The  liver  metabolizes  albuterol  extensively  to  inactive  compounds. 
Excretion  of  albuterol  occurs  through  the  urine  and  faeces.  After  oral 
inhalation, 80—100% of a dose is excreted via the kidneys within 72 hours; 
up to 10% may be eliminated in feces. After oral administration, 75% of a 
dose is excreted in urine within 72 hours as metabolites; 4% may be found in 
faeces. The elimination half-life of albuterol ranges from 2.7-5 hours, with 
orally  administered  albuterol  having  a  shorter  half-life  than  the  inhaled 
product
Indications:
1. Bronchodilator  for  in asthma,  chronic bronchitis,  emphysema 
and other condition. 
Contra indications. 
1. Salbutamol preparations should not be used to manage threatened 
abortions. 
2. Inhaled  salbutamol  is  not  appropriate  for  the  managements  of 
premature labour.
3. Hyper sensation to salbutamol 
Adverse reaction:
Life- threatening effects:
Electro cardio graphic evidence of myocardial ischemia was reported 
in healthy pregnant women was reported. 
Acute over dosage:
Overdose of albuterol between 5 to 240 mg produced no fatalities. 
The commonest symptoms are tremor, flushing, agitation and palpitation to 
tachycardia.
Severe (or) irreversible adverse effects:
(i) Ventricular  ectopic  beats  have  been reported  during infusion of 
albuterol in one pregnant women.
(ii) Angina accompanied by ECG charges was reported in 3 patients 
with ischemic heart  disease and either  Asthma (or)  copd during 
oxygen driver nebulization in hospital.
Symptomatic adverse effects:
It includes tremor, anxiety, muscle cramps, headache and palpitations
Drug dosage and administration:
Neonates: The drug is rarely in the neonatal period.
Children: Suitable and doses for children under 7 years are syrup / 
tablets 2 mg 3 times daily. Slow – release tablets 4 mg at 
night, respirator solution 1mg four times daily.
Pregnant  women: It  should  be  used  in  the  first  trimester  unit 
essential.
Elder patients: Inability to use pressurized aerosol, Rotocaps  may be 
needed  oral  or  high  doses  more  likely  to  provoke  angina,  cardiac 
arrymias (or) patients with prostatism,  urinary retention.
Drug interactions:
Potentially hazardous interaction:
Treatment with diuretics may augment the hypokalemia that occurs 
with  large  doses  of  albuterol.   Effects  of  albuterol  are  inhibited   β1 
antagonist. 
Potentially useful interactions:
The theoretical synergism of β1  Stimulants and theophyline were as 
bronchodilators.
 Table No.3 Salbutamol Sulphate Commercially Availed Product
S.No Brand Name Dose form Dose Available Company  
1 Ventrolin CR  Capsule 
Syrup 
MDI
8mg
2mg/5ml
100 mcg/puft
GSK
GSK
GSK
2 Servent Inhaler 50 mcg/ puff GSK
3 Venmix Syrup 2 mg / 5ml Unimaek
4 Salbetol Tablet 2mg
4mg
FDC
5 Salbid tablet 2mg
4mg
Micro labs
6 Asthalin tablet 2mg
4mg
cipla
6.2 EXCIPIENTS PROFILE
1. Saccharin sodium47
Synonyms: Soluble saccharin,  
Sodium – o- benzo sulfamide soluble glucoside
Non- Proprietary Names:
USP: Saccharin sodium
BP: Saccharin sodium
Chemical Name: 1,2 Benzisothiazol – 3 (2H) – 1,1, dioxide, sodium salt
1,2 Benziso thiazolin – 3  cone)- 1,1, dioxide,  
 Sodium salt dehydrate (6155 – 57-B)
Anhydrous (128 – 44 – 9)
Description:
A white odorless (or) faintly aromatic, effervescent crystalline powder 
with intensity sweet taste, both forms of saccharin sodium (76% and 84%) 
are identical in the appearance.
2. Crospovidone50
Synonym Kollidon CL, 
Kollidon CL – M, 
Polyplasdone – XL,
Polyplasdone XL10
Chemical Name
1- Ethenyl-2- Pyrrolidinone homopolymer
Nonproprietary Names
BP- Crospovidone
USPNF- Crospovidone
Description 
Crospovidone is white to creamy white finely divided, free flowing 
practically tasteless / nearly odorless, hygroscopic powder.
Functional Category
Tablet Disintegrant 
Application in Pharmaceutical Formulation 
Crospovidone  is  water  insoluble  tablet  disintegrate  and  dissolution 
agent used at 2-5% concentration in tablet prepared by direct compression / 
wet and dry granulation methods. It rapidly exhibits high capillary activity 
and  pronounced  hydration  capacity  with  little  tendency  of  crospovidone 
strongly influence disintegration of tablets.
Large particles provide a faster disintegration than smaller particles. 
Crospovidone can also be used as solubility enhancer with the technique of 
co-  evaporation.  It  can  be  also  used  to  enhance  the  solubility  of  poorly 
soluble drugs. The drug is adsorbed on to crospovindone in the presence of a 
suitable solvent and the solvent is then evaporated. This technique results in 
faster dissolution rate.
3. Sodium Starch Glycolate (SSG) 49 
Synonyms Carboxymethy1 starch (sodium salt),
Explotab, 
Primojel.
Chemical Name 
Sodium carboxymethy1 starch.
Nonproprietary Names 
BP- Sodium starch glycolate.
USP NF- Sodium starch glycolate. 
Description 
Sodium starch glycolate is a white to off – white odorless, tasteless, 
free  flowing  powder.  It  consists  of  oval  or  spherical  granules  30-100 
micrometers in diameter with some less spherical granules ranging from 10-
35 micrometer in diameter.
Applications 
Sodium starch  glycolate  is  widely  used  in  oral  pharmaceuticals  as 
disintegrant in capsule and tablet formulation. It is commonly used in tablets 
prepared by either direct compression or wet granulation process. The usual 
concentration employed in formulation is between 2-8% with the optimal 
concentration  of  about  4%.  Although  in  may  case  2%  is  sufficient 
disintegration  occurs  by  rapid  uptake  of  water  followed  by  rapid  and 
enormous swelling. 
Although the  effectiveness  of  many  disintegrate  is  affected  by  the 
presence  of  hydrophobic  excipients  such  as  lubricant,  the  disintegrant 
efficacy of sodium starch glycolate  is unimpaired by increasing the tablets 
compression pressure also appears to have no effect on disintegration time.
4. Croscarmellose Sodium 50
Synonyms Ac- Di- Sol, 
Cross  –  linked  carboxy  methylcellulose  sodium, 
Primellose, solutab.
Chemical Names
Cellulose  Carboxy  Methy1  Ether,  Sodium  salt, 
cross- linked. 
Description 
Sodium starch glycolate is a white to off- white odorless,  tasteless, 
free  flowing  powder.  It  consists  of  oval  or  spherical  granules  30-100 
micrometers in diameter with some less spherical granules ranging from 10-
35 micrometer in diameter.
Applications
Sodium starch  glycolate  is  widely  used  in  oral  pharmaceuticals  as 
disintegrate in capsule and tablet formulation. It is commonly used in tablets 
prepared  by  either  compression  or  wet  granulation  process.  The  usual 
concentration employed in formulation is between 2-8% with  the optimal 
concentration  of  about   4%.  Although  is  many  cases  2%  is  sufficient 
disintegration  occurs  by  rapid  uptake  of  water  followed  by  rapid  and 
enormous swelling.
Although  the  effectiveness  of  many  disintegrant  is  affected  by  the 
presences  of  hydrophobic  excipients  such  as  lubricant,  the  disintegrant 
efficacy of sodium starch glycolate is unimpaired by increasing the tablets 
compression pressure also appears to have no effect on disintegration time.
5. Mannitol 52
Synonym             Cordypic acid, 1, 2, 3, 4, 5, 6. - Hexane hexol
Chemical Names.
D-mannitol
Nonproprietary Names 
BP- Mannitol.
USP NF- Mannitol
Description
D-  Mannitol  is  a  hexahydric  alcohol  related  to  mannose  and  is 
isomeric with sorbitol. It is occurs as white, odorless, crystalline power, or 
free – flowing granules it has sweet taste, approximately as sweet as glucose 
and half sweet as sucrose. It imparts cooling sensation in mouth.
Application 
Mannitol is widely used in pharmaceuticals formulations as sweetning 
agent. In pharmaceutical preparations, it primarily used as diluents. Due to 
its non hygroscopic nature. It may be used with moisture sensitive active 
ingredients. Mannitol is commonly used as excipients in   manufacture of 
chewable tablet formulation because of its negative heat solution, sweetness 
and mouth feel.
6. Magnesium Stearate53
Synonyms Stearic acid magnesium salt, 
Magnesium octadecanoate
Chemical Name
Octadecanoic acid magnesium salt
Nonproprietary Names
BP- Magnesium stearate
PhEur – Magnesli stearate
USPNF- Magnesium stearate
Description 
Magnesium stearate is a fine, white, precipitated, milled impalatable 
powder of low bulk density, having a faint, characteristic odor and taste. The 
powder is greasy to touch and readily adheres to skin.
Applications
Magnesium  stearate  is  widely  used  in  cosmetics,  foods,  and 
pharmaceuticals.  It  is  primarily  used  as  lubricant  in  capsule  and  tablet 
manufacture at concentration between 0.25-50% concentrations.   
7. Povidone 
  Non-proprietary Name       Povidone
 Functional Category Tablet binder
                                                  Suspending agent
 Synonyms                               Polyvidone, Polyvinylpyrolidine, 
 PVP, Kollidon, Plasdone.
Chemical Name  2-pyrrolidinone, 1, ethyl homopolymer-
1- vinyl-2- pyrrollidionone polymer
Typical properties  
Density     1.17 to 1.18 gm/cm3
Solubility  Readily soluble in water up to 60 %,
           freely soluble in many organic 
solvents
Table No.4
Application of Povidone in Pharmaceutical Formulation
S.No Use Concentration 
1. Carrier for drug 10 - 25 %
2. Dispersing agent Up to 5 %
3.  Suspending agent Up to 5 %
4. Tablet binder, diluents, coating agent 0.5 - 5 %
7. MATERIALS AND METHODS
7.1 List of Instruments Used
Table No.5
S. 
No
Instrument  Name Company 
1. Digital weighing balance Sartorius
2. Tray drier Mixofill
3. Rotary tablet punching machine Rimeck minipress
4. pH  Meter Thermovorision 
5. Tap density tester Electrolab
6. Mechanical sieve shaker Retsch
7. Friability tester Roche 
8. Hardness tester Pfizer
9. UV-Visible spectrophotometer Shimandzu
10. Dissolution tester USP Electrolab
11 Environment  Chamber Heco
7.2 List of Exponents and Chemical Used
Table No.6
S.No Instrument Name Company
1  Sodium starch glycolate Ranchem, Ranbaxy
2 Cros- povidone Ranchem, Rambaxy 
3 Cros- carmellose sodium Ranchem, Ranbaxy 
4 Poly- vinyl pyrrolidine FMC, Germany
5 Isopropyl alcohol Microfine chemicals
6 Mannitol BASF Germany
7 Sodium saccharin Rankem, ranbaxy
8 Magnesium sterate Ranchem lab chemicals
9 Talc Nice chemical Pvt limited
10 Orange flavour IFF Ltd,Chennai
11 Lactose monohydrale Lactose, India
7.3 PREFORMULATION STUDIES
IDENTICATION AND CHARACTERIZAITON OF SALBUTAMOL 
SULPHATE
Infra-Red Absorption spectrum
The IR spectrum of salbutamol was determined and recorded using IR 
Spectro photometer.  The KBr pellet  method was used for  preparation of 
salbutamol sample 
.
UV Spectrophotometer method
Weigh  accurately  10  mg  of  pure  salbutamol  drug  was  taken  and 
dissolved in 100ml of water. This made up to 100 mcg/ ml solution. From 
this  stock   solution from  0.5ml was taken and diluted with phosphate 
buffer pH 6.2 up to 10 ml. then absorbance was measured at 276 nm using 
UV – spectrophotometer.
Melting point
The melting point of salbutamol was determined by capillary method.
7.4 Standard Curve for Salbutamol Suphate in Sorenson’s Buffer
Solution pH 6.2  56
Materials
 Salbutamol Sulpahate
 Sorenson’s Buffer Solution pH 6.2
Procedure
100 mg of salbutamol was accurately weighted and then dissolved in 
100 ml of water. This solution is having concentration 100 mg / ml. From 
this  stock solution 50,  100,150,200,250,300 mg/ml  by diluting phosphate 
buffer  6.2  pH.  Absorbance  was  measured  at  276  nm  using  UV- 
spectrophotometer  (Shimadzu)  Graph  is  plotted  for  absorbance  UV 
concentration.     
Table No.7 Standard Curve for Salbutamol Suphate
S.No Concentration  in mcg/ml Absorbance at 276 nm
1 50 0.336
2 100 0.580
3 15 0.889
4 200 1.145
5 250 1.427
6 300 1.740
R  - 0.9994
A  - 0.0378
B  - 0.0056
Figure No.1 Standard Curve for Salbutamol Suphate
Standard Curve of Salbutamol sulphate
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Solubility66
The  approximate  solubility’s  of  substance  are  indicated  by  the 
descriptive terms in the accompanying table. 
Table No.8
  
   Descriptive term                Parts of solvent require for 
                         1 Part of solute.
1. Very soluble Lees than 1
2. Freely soluble From 1 to 10
3. Soluble From 10 to 30
4. Sparingly soluble From 30 to 100
5. Slightly soluble From 100 to 1,000
6. Very  Slightly soluble From  1,000  to 
10,000
7. Practically insoluble (or)          Greater than (or) equal to
          Insoluble 10,000.
7.5 Selection of Exicipients
Table No.9
Name of the Substance Use in formulation
1. Salbutamol sulphate Drug
2. Lactose monohydrate Diluent 
3. Mannitol Diluent 
4. Sodium Starch  glycolate Super Disintegrant
5. Cros- povidone Super Disintegrant
6. Cros- carmellose sodium Super disintegrant 
7. Sacharin sodium Sweetning agent 
8. Povidone Binder
9. Orange   flavours  Flavoluring agent
10. Magnesium sterate                                           lubricant
11. Talc Anti adhesive.
Formulation  of  salbutamol  sulphate  mouth  dissolving  tablets  using 
super disintegrants
The tablet  consisted  of  drug,  mannitol,  orange flavour,  magnesium 
state,  talc  and various  concentrations  of  lactose  mono hydrate  and super 
disintegrants. The weight of tablet batch was kept constant. All the batches 
of 50 tablets  were prepared by wet granulation process using 10- station 
Rotatory tablet punching machine.
Control Formulation (Formulation with out super disintegrants)
Table No.10
S.No Ingredients Quantity F1 (mg )
  1. Salbutamol Sulphate 4
  2. PVP             3
  3. Mannitol 30
  4. Sodium saccharin  1
  5. Orange flavour 1.5
  6. Lactose mono hydrate 110.5mg
  7. Total 150
7.6 DESIGN OF FORMULATION 
Table No.11 Formulation of Tablet Containing Sodium Starch 
Glycolate as Super disintegrants 
S.No Name of Ingredients     Quantity      (mg)
                                                                                        F2                F3
  1. Salbutamol sulphate         4          4
    2. Sodium starch glycollate       12      15
  3. PVP        3       3
  4. Mannitol       30      30
  5. Saccharin sodium       1                   1
  6. Orange flavour 1.5 mg           1.5 mg
  7. Lactose    98.5                 97
  8. Total   150      150
Table No.12 Formulation of Tablet Containing Crospovidone 
as Super Disintegrant
S.No Name of Ingredients     Quantity                      (mg)
                                                                                 F4                             F5 
  1. Salbutamol sulphate             4                      4
    2. Sodium starch glycollate 12                         15   
  3. PVP  3           3
  4. Mannitol 30         30
  5. Saccharin sodium  1                          1
  6. Orange flavour 1.5                      1.5
  7. Lactose 98.5                     97
  Total 150       150
 
Design of formulation cros – carmuellose  sodium as a super 
disintegrants
Formulation of tablet containg cros – carmulose sodium as a 
superdisintegrants.
Table No.13
 
  S.No Name of Ingredients       Quantity                 (mg)
                                                                                    F6                      F7
  1. Salbutamol sulphate 4                 4
    2. Sodium starch glycolate 12                          15
  3. PVP  3            3
  4. Mannitol 30          30
  5. Saccharin sodium  1                              1
  6. Orange flavour 1.5 mg               1.5 mg
  7. Lactose 98.5                        97
  Total 150         150
7.7 Evaluation of Fast Dissolving Tablets65
Preformulation studies
Angle of repose
With care, dynamic angle of repose measurement can be replicated 
with relative standard deviation of approximately 2% they are particularly 
sensitive to change in particle size distribution and to moisture content and 
they provide rapid means of monitoring significant batch difference in these 
respells. 
     
 =tanӨ -1h/r
Where, 
                  - Angle of reposeӨ
                 H-Height of the pile
                 R- Radius of the base of the conical pile
Angle of repose was determined by using funnel method. Powder was 
paired from a funnel  that  can be raised vertically  until  a  maximum cone 
heights, it was obtained. Diameter of heap, d was measured. 
The angle of repose calculated by above formula
.
Table No.14 Angle of Repose as indicating of powder flow – properties
Angle of repose (Degrees) Types or flow
<20  Excellent
20.30 Good
30.34 Passable
           >40 Very poor
Bulk Density 66
Bulk density is of great importance when one considers the size of 
high dose capsule product (or) me homogeneity of how dose formulation in 
which where is large difference in drug and Excipients densities. Apparent 
bulk density is determined by pouring pre sieved (40 sieve) bulk drug into a 
graduated cylinder via a large and measuring the volume and weight “as it 
as”.
Powder flow properties 64
One of the ways of measurement of free flowing ability of powder is 
compressibility. 
Carr’s index = (Vi-Vt)/Vi X100
Vi = Tapped density
Vt = Initial bulk density
Process chart
Drug
Mixing
Polymer Excipients 
Granulating agent
Granulation
Sieving
Drying
Mixing   Lubricant
        Glidant 
Compression
Evaluation of tablets
Weight variation
      Weight of 20 tablets was determined. Form that average weight was 
calculated. Then individual tablet were weighed and the individual weight 
was compared with the average  weight.
Specification as IP
Table No.15
S.No Average weight of the tablets Percentage deviation
1 80 mg or less 10
2 More than 80 mg but less than 250 mg 7.5
3 250mg or more 5
Hardness
      Although there is no official test for tablet hardness this property must 
be controlled during production to ensure that the product is firm enough to 
withstand handling without breaking, chipping etc., the hardness of a tablet 
is  indicative  of  its  tensile  strength  and  is  measured  in  term of  pressure 
required to crush it when placed on its edge. Hardness of about 5 kg/cm2 is 
considered to be minimum for uncoated tablets for mechanical stability. The 
hardness had influence on disintegration and dissolution times. Hardness is 
the factor that affects the bioavailability.
Friability
        Friability generally refers to loss in weight of tablets in the container 
due  to  chipping,  abrasion,  and  erosion.  The  standard  device  available  is 
“Friabilators”  (Consist  of  circular  plastic  chamber,  a  divided  into  two 
compartments. The chamber rotates at a speed of 25 r.p.m and drops tablets 
by distance of 15 cm). The weight loss should not be more than one percent.
Formula
 Percentage Friability = (initial weight-final weight/initial weight) Χ 100
Procedure
       10 tablets are weighed and transferred in to Friabilator. Then after 
100 revolutions  per  minute  the  tablets  were  unloaded and  weight  of  the 
tablets was noted. The difference should not exceed one percent.
Disintegration time
         Tablet was added to 100 ml distilled water at 37oC± 0.5 oC. Time 
required for complete dispersion of a tablet was measured win help of digital 
tablet disintegration test apparitions. 
Uniformity of content:
        . 
Procedure
     Crush two tablets, taken the powder equivalent of dose 10mg, add 100 
ml ethanol (100mg/ml). Take 0.5ml and diluted with phosphate buffer 6.2 
PH (0.5mg/ml)  and  it  was  filtered;  measure  the  absorbance  of  resulting 
solution at 276 nm using UV- spectro photometric ally.
 
Dissolution study
Dissolution rate was studied by using USP type II apparatus under 
following experimental condition 
- 50 rpm
- 900  ml  Phosphate  buffer  6.2  Sorenson’s 
sodium
- 37± 0.5 oC as a temperature of dissolution 
medium.
Aliquot equal to 5rnl of dissection medium was withdrawn of specific 
time interval and it was filtered. Absorption of filtered solution was checked 
by  276  nm  and  drug  content  was  determined  from  standard  calibration 
curve.
In vitro dispersion time
In  vitro  dispersion  time  was  measured  by  dropping  a  tablet  in  a 
measuring cylinder containing 6 ml of pH 6.8 (simulated saliva fluid). There 
tablets from each formulating were randomly selected and vitro dispersion 
time was preformed 
Wetting time:
The method was followed to measure tablet – wetting time a price of 
tissue paper folder twice was placed in small pertidish (6.5cm) containing 
6ml  of  simulated  saliva  pH a  tablet  put  on  the  paper,  and  the  time  for 
complete wetting was measured. 3 trials of each batch were performed and 
standard deviation was also determined.
7.8 ACCELERATED    STABILITY    STUDIES
Stability 
        Stability is officially defined as the time lapse during which the drug 
product retains the same properties and characteristics that it possessed at the 
time of manufacture. This process begins at early devolvement phases.
.        Instability  in  modern  formulation  is  often  detectable  only  after 
considerable storage period under normal condition. To assess the stability 
of a formulated product its usual to expose it to high stress conditions to 
enhance its detoriation and therefore the time required for testing is reduce
 common high stress like temperature and humidity. This will eliminate 
unsatisfactory formulation.
Strategy of stability testing 
1. The study of drug decomposition kinetics
2. The development of stability dosage form.
3. Establishment  of  expiration  date  for  commercially  available  drug 
product is some of the needs of stability testing.
4. Data  form  stability  studies  should  be  provided  on  at  least  three 
primary batches of the drug product. 
5. The batches should be manufactured to a minimum of pilot scale.
6. Important point of view of the safety of the patient, patient relieves a 
uniform dose of drug throughout the shelf life of the product.
The Stability Storage condition
Table No.16
S.No Study Storage condition Minimum 
period
1. Long-term study 25° C ± 2° C 
60 % ± 5% RH
12 month
2. Intermediate study 30 ° C ± 2° C
60 % ±5 % RH
6 month
3. Accelerated study 40° C ± 2 ° C
75% ±5 % RH
6 month
Procedure
    Selected batches were placed in a high density polyethylene container, 
blister pack, stripe pack etc. they are kept in stability chamber maintained at 
40°C and 75 % RH. The stability studies were carried out for a period of one 
month.  The  tablets  were  tested  and  checked  for  the  above  mention 
specification.
8. Results and Discussion
Preformulation Studies
Drug identification – by Spectrophotometer method (UV)
Table No.16 UV- Absorbance of Salbutamol sulphate in 0.1 N HCL
S. No Concentration Absorbance at 
276nm
1 300 mcg/ml 1.673
    
Table No.17 UV-Absorbance of Salbutamol Sulphate in water
Discussion
• The UV- absorbances of the Salbutamol sulphate were performed at 
different concentration in different medium and their wavelength were 
found and compared with monograph. 
S. No Concentration Absorbance at 276 
nm
1 300 mcg/ml 1.621
FigureNo.2 UV- Absorbance of Salbutamol sulphate in 0.1 N HCL
Figure No. 3 UV-Absorbance of Salbutamol Sulphate in water
Infra-Red Spectrum
Infra-Red Spectrum 
Table No.19 IR Spectrum of Salbutamol Sulphate 
Figure No.4 IR Spectrum of Salbutamol Sulphate 
Discussion
• The  structure  of  Salbutamol  sulphate  was  confirmed  by  IR 
spectrum and the spectrum was compared with standard graph 
in monograph.
S.No Wave Number in 
cm-1
Functional Group
1 31275 OH and NH  Stretching
2 2797 -CH  Aliphatic
3 2454 -CH for – CH2 - Chain
4 1616 Aromatic ring C= C Stretching
5 1442 OH Phenolic Stretching
6 1118 Aromatic CH Bending
7 1389 S=O Asymmetric 
                      H2SO4
Figure.No.5 IR Cros-Carmellose Sodium
Infra-Red Spectrum 
Table No.20 IR Cros-Carmellose Sodium
S.No Wave Number in 
cm-1
Functional Group
1 3437 -OH/NH Stretching
2 2925 -CH Aliphatic Stretching
3 2362 -CH (– CH2 -) Stretching
4 1618 C=C Aromatic Stretching
5 1424 OH Phenolic Stretching
6 1268 C-O-C Ether Stretching
7 1114 Ar –O–CH2  Stretching
Discussion
• The structure cros-carmellose sodium of was confirmed by IR 
spectrum. 
Figure No.6 IR Spectrum of Salbutamol Sulphate + Cros-Carmellose 
Sodium
ACTIVE PHARMACEUTICAL   CONSIDERATION
Infra-Red Spectrum
Table No.21 IR Spectrum of Salbutamol Sulphate + Cros-Carmellose  
Sodium
S.No Wave Number in 
cm-1
Functional Group
1 31275 OH and NH  Stretching
2 2797 -CH  Aliphatic
3 2454 -CH for – CH2 - Chain
4 1616 Aromatic ring C= C Stretching
5 1442 OH Phenolic Stretching
6 1118 Aromatic CH Bending
7 1389 S=O Asymmetric 
Discussion
• All peaks of Salbutamol sulphate are present in the mixture of 
cros-carmellose sodium and salbutamol sulphate; it shows the 
compatibility  of  Salbutamol  sulphate  with  cros-carmellose 
sodium.
Solubility Studies 
• Freely Soluble in the water 
• Slightly soluble in 95% Ethanol
Melting point 155° C
  
Active pharmaceutical Consideration
Table No.22 Powder Properties   of Formulation Containing Super 
Disintegrants
 
Formulation 
code
*Bulk density
gm/cm3
*Angle of 
repose
Carr’s index
%
Type of flow
F1 0.333 21° 41’ 15.62 Excellent
F2 0.348 21° 43’ 11.90 Excellent
F3 0.375 21° 20’ 12.12 Excellent
F4 0.352 24° 09’ 14.02 Excellent
F5 0.353 21° 43’ 17.00 Good
F6 0.344 20° 10’ 15.62 Excellent
F7 0.354 20° 57’ 14.70 Excellent
* Average value of three observations.
Discussion
• The values of angle of repose and Carr’s index were less than 25° and 
15  %  respectively,  hence  the  flow  properties  of  all  formulations 
complied within the limits.
Evaluation of Mouth Dissolving Tablets
Table No.23 Tableting Properties of Control Formulation and 
Formulation Containing Sodium Starch Glycolate as a 
Superdisintergrants
(8% And 10%)
S.No Formulation Properties F1(Control) F2 F3
1 Weight variation  % 1.431 1.318 1.385
2 Hardness in kg/cm2 3.9±0.63 3.4±0.32 3.2±0.30
3 Friability % 0.252 0.318 0.398
4 Uniformity of content 98.65 98.07 98.17
5 Disintegration time in sec 162±1.48 59±2.70 49±4.1
6 Wetting time in sec 141±1.0 35.6±2.40 26.6 ±2.26
Discussion
• By comparing the properties of the control tablet with other tablets 
prepared by using various superdisintegrants, it was found that  the 
control  tablets  had greater  hardness  and disintegration  time  due  to 
absence of the superdisintegrants in the control formulation.
• The control formulation had also shown least friability.
• All  physical  parameters  of  the  prepared  tablets  compile   with 
monograph  (Indian Pharmacopoeia)
Table No.24 Tableting Properties of Control Formulation and 
Formulation Containing Crospovidone as a Superdisintegrants 
(8% and 10%)
S.No Formulation Properties F1(Control) F4 F5
1 Weight variation  % 1.431 1.366 1.358
2 Hardness in kg/cm2 3.9±0.63 3.7±0.01 3.5±0.63
3 Friability % 0.252 0.398 0.318
4 Uniformity of content 98.65 99.05 98.45
5 Disintegration time in sec 162±1.48 60± 0.77 55± 1.0
6 Wetting time in sec 141±1.0 13.3 ±1.65 11.0 ±1.0
Discussion
• By comparing the properties of the control tablet with other tablets 
prepared by using various superdisintegrants, it was found that control 
tablets had greater hardness and disintegration time due to absence of 
the superdisintegrants in the control formulation.
• The control formulation had also shown least friability.
• All  physical  parameters  of  the  prepared  tablets  compile  with 
monograph (Indian Pharmacopoeia).
• As the concentration of the crospovidone increases the disintegration 
time decreases.
Table No.25 Tableting Properties of Control Formulation and 
Formulation Containing Cros-Carmellose sodium as a 
Superdisintegrants 
(8% And 10%)
S.No Formulation Properties F1(Control) F5 F6
1 Weight variation  % 1.431 1.358 1.363
2 Hardness in kg/cm2 3.9±0.63 3.3±1.18 3.5±0.63
3 Friability % 0.252 0.387 0.376
4 Uniformity of content 98.65 99.01 99.20
5 Disintegration time in sec 162±1.48 50±1.0 42±0.77
6 Wetting time in sec 141±1.0 17.6±1.74 16.3±1.28
Discussion
• By comparing the properties of the control tablet with other tablets 
prepared by using various superdisintegrants, it was found that control 
tablets had greater hardness and disintegration time due to absence of 
the superdisintegrants in the control formulation.
• The control formulation had also shown least friability.
• All  physical  parameters  of  the  prepared  tablets  compile  with 
monograph (Indian Pharmacopoeia).
• As  the  concentration  of  the  cros-carmellose  sodium increases  the 
disintegration time decreases.
In vitro Drug Release
Dissolution  profile  for  mouth  dissolving  tablets  containing 
salbutamol  sulphate  prepared  by  using  Sodium  Starch  Glycolate  in 
Sorenson’s buffer (pH 6.2)
Table No.26 In vitro Drug Release
Time in 
minutes 
%Drug Release % Drug Release %Drug Release
F1 (Control) F2 F3
2 - 36.96 40.98
4 - 40.98 53.03
6 - 49.00 65.08
8 - 53.03 85.17
10 - 57.05 89.19
12 - 65.08 89.19
14 - 69.10 -
16 - 77.16 -
18 - 81.16 -
20 - 81.16 -
22 - - -
24 - - -
26 - - -
28 - - -
30 - - -
32 - - -
34 0.80 - -
36 4.80 - -
38 12.85 - -
40 20.79 - -
42 24.91 - -
44 28.92 - -
46 32.94 - -
48 36.96 - -
50 40.98 - -
52 49.00 - -
54 53.03 - -
56 57.07 - -
58 65.08 - -
60 69.10 - -
Discussion 
• Dissolution behaviour of controlled tablet has shown in table no.26 
and figure no.1 and it was observed that controlled tablets has shown 
69  percent  drug  release  at  60 th minute  and  the   drug  was  not 
completely  released  due  to  absences  of  superdisintegrants  in  the 
formulation.
• Dissolution profile of mouth dissolving tablets containing salbutamol 
sulphate by using sodium starch glycolate has shown in table no.26 
and figure no.2 and 3 it  was observed that  the tablet  containing 8 
percent (F2) and 10 percent (F3) sodium starch glycolate had shown 
the drug release 81.16 percentage and 89.19 percentage respectively at 
20 th and 12 th minutes, from the result that inferred with increase in the 
concentration of sodium starch glycolate and drug release was also 
rapid.
 
Figure No.7 In vitro Drug Release for control formulation 
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Figure No.8 In vitro Drug Release for F2 Formulation 
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Figure No.9  In vitro Drug Release for F3 Formulation 
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Figure No.10 Comparative In vitro Drug Release for F1, F2 and F3
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Table No.27 In vitro Drug Release
Dissolution profile for mouth dissolving tablets containing salbutamol 
sulphate prepared by using Crospovidone in Sorenson’s buffer (pH 6.2) 
Table No.27 In vitro Drug Release
Time in 
minutes 
% Drug Release % Drug Release % Drug Release
F1 (Control) F4 F5
2 - 32.94 49.00
4 - 40.98 57.05
6 - 53.03 69.10
8 - 65.08 89.19
10 - 77.16 93.20
12 - 89.19 93.20
14 - 89.19 -
16 - -
18 - -
20 - -
22 - - -
24 - - -
26 - - -
28 - - -
30 - - -
32 - - -
34 0.80 - -
36 4.80 - -
38 12.85 - -
40 20.79 - -
42 24.91 - -
44 28.92 - -
46 32.94 - -
48 36.96 - -
50 40.98 - -
52 49.00 - -
54 53.03 - -
56 57.07 - -
58 65.08 - -
60 69.10 - -
Discussion 
• Dissolution behaviour of controlled tablet has shown in table no.27 
and figure no.1 and it was observed that controlled tablets has shown 
69 percent drug release at 60 th minute  and  drug was not completely 
released  due to absences of superdisintegrant in the formulation.
• Dissolution profile of mouth dissolving tablets containing salbutamol 
sulphate by using crospovidone has shown in table no.27 and figure 
no.4 and 5 it was obsever that the tablet containing 8 percent (F4) and 
10  percent  (F5)  crospovidone  had  shown  the  drug  release  89.19 
percentage and 93.20 percentage respectively at 14 th and 12 th minutes, 
from the result that inferred that drug release increases with    increase 
in the concentration of crospovidone comparing with sodium starch 
glycolate,the drug release was rapid.
Figure No.1 1 In vitro Drug Release for F4 Formulation 
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Figure No.12 In vitro Drug Release for F5 Formulation 
In vitro Drug Release
0
10
20
30
40
50
60
70
80
90
100
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52 54 56 58 60
Time in Minutes
% 
Dr
ug
 R
ele
as
e
F5
Figure No.13 Comparative In vitro Drug Release for F1, F4 and F5
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Table No.28 In vitro Drug Release
Dissolution  profile  for  mouth  dissolving  tablets  containing 
salbutamol  sulphate  prepared  by  using  Cros-Carmellose  Sodium  in 
Sorenson’s buffer (pH 6.2)
Time in 
minutes 
% Drug Release % Drug Release % Drug Release
F1 (Control) F6 F7
2 - 53.03 57.05
4 - 57.05 69.10
6 - 65.08 85.17
8 - 67.10 89.19
10 - 85.17 97.23
12 - 89.19 -
14 - 93.20 -
16 - - -
18 - - -
20 - - -
22 - - -
24 - - -
26 - - -
28 - - -
30 - - -
32 - - -
34 0.80 - -
36 4.80 - -
38 12.85 - -
40 20.79 - -
42 24.91 - -
44 28.92 - -
46 32.94 - -
48 36.96 - -
50 40.98 - -
52 49.00 - -
54 53.03 - -
56 57.07 - -
58 65.08 - -
60 69.10 - -
Discussion
• Dissolution behaviours of controlled tablet has shown in table no.27 
and figure no.1 and it was observed that controlled tablets has shown 
69 percent drug released at 60 th minute and drug was not completely 
released due to absences of superdisintegrants in the formulation.
• Dissolution profile of mouth dissolving tablets containing salbutamol 
sulphate by using cros-carmellose sodium has shown in table no.27 
and  figure  no.6  and  7  it  was  obsever  that  the  tablet  containing  8 
percent (F4) and 10 percent (F5) cros-carmellose sodium had shown 
the drug release 93.20  percentage and 97.23 percentage respectively 
at 14 th and 10  th minutes, it was found  that 97.23 percentage drug 
release which was quicker than both control and formulation prepared 
by other superdisintegrants.
• Cros-carmellose  sodium is  pivotal  step  in  rapid  disintegration  and 
ultimately quick release of drug from the tablets.
.
Figure No.14 In vitro Drug Release for F6 Formulation 
Figure No. 15 In vitro Drug Release for F7 Formulation
Figure No.16 Comparative In vitro Drug Release for F1, F4 and F5
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Figure No.15 In vitro Drug Release for F7 Formulation 
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Figure No.16 In vitro Drug Release for F6,F7,F5 Formulation 
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Accelerated Stability studies
TableNo.29 Stability Studies Reports
Time 
period 
in 
weeks
Parameters
Weight in 
mg
Hardness 
kg/cm2
Drug 
Content 
%
Disintegration 
time in sec
Wetting time in 
sec
0 day 150 3.5 42 16.3 99.30
1st week 150 3.5 42 16.3 99.25
2nd week 150 3.5 42 16.3 99.25
3rd week 151 3.5 42 16.3 99.20
4th week 151 3.5 42 16.3 99.00
Discussion 
The stability studies of the mouth dissolving tablets were studied as per ICH 
guidelines   for the period of one month and the percentage drug content 
of the formulation complied within the limit as per ICH guidelines.
9. Summary and Conclusion
Asthma is defined as chronic inflammatory disorder of the airways in 
which  many  cells  a  mast  cells,  esinofils,  T-lymphocytes,  macrophage, 
neutrophils  and  epithelial  cells  and  other  cellular  elements  play  role  in 
susceptible individual recurrent episodes  of wheezing breathless chest fight 
and coughing
• Anti asthmatics are typically corticosteroids, leuckotriene cormones, 
antihistamines, beta two agonist theopylline.
• Salbutamol sulphate is B2  adrenergic agonist that stimulator receptors 
of smooth muscles in the lungs. Salbutamol is believed to work by 
adenylate cyclase, the enzyme responsible for generating cyclic Amp 
an intracellular mediator. Increased cylase Amp lead to activating of 
intra  cellular  ionized  cyclic  Amp  prokinase  A  which  inhibits 
phosphorylation of myosin and lowers the intracellular ionic calcium 
concentration,  resulting  in  relaxation  of  bronchial    and  tracheal 
smooth   muscles,  which  in  turn  relieves  branchospasm,  reducer 
airway  resistance,  facilitates  mucous  drainage  and  increases  vital 
capacity
• Geriatric, pediatric and psychiatric  patients were less conventional by 
means of taking their medication it is difficult  for many patients to 
swallow  tablets  and  capsules.  Hence  they  do  not  comply  with 
prescription which results in high incidence of non compliance and 
ineffective  therapy.  Such  problems  can  be  resolved  by  means  of 
mouth dissolving tablets. 
• Several  methods  have  been  reported  for  the  formulation  of  mouth 
dissolving dosage forms, which required water soluble drugs. among 
different approaches for preparing mouth dissolving tablets, By using 
super disintegrant is one of them 
• Rapidly disintegration tablet is formulated by wet granulation method 
using  superdisintegrant  such  as  sodium  starch  glycolate, 
crospovidone, cros-carmellose sodium and the disintegration time  of 
the mouth dissolving tablets were compared with  control formulation 
(with out super disinter grants). 
• Powder blend of all formulation had shown good flowability 
• Mouth  dissolving  tablets  of  salbutamol  sulphate  were  made  with 
different  concentration  of  superdisintegrants  and  used  for  tablet 
properties and dissolution profile. 
• The  obtained  tablet  were  subjected  to  official  and  unofficial 
evaluation  test  via  uniformity  of  weight,   hardness,  friability  test, 
content  uniformity,  disintegration  time  and  dissolution  test 
respectively.
• The evaluation study of the tablets   reported to be complied with 
official  and  the  permissible  limits  him  reference  to  official 
monograph.
• The dissolution study was carried out to determine the profile of drug 
release from the formulation 
• The dissolution profile for control tablet was observed that 70% drug 
relecese within one hour.
• Dissolution  profile  for  tablet  prepared  by  F2  and F3  as  formulation 
containing  8%  and  10%  of  sodium  starch  glycolate  as 
superdisintegrants respectively. It was observed that 90% drug release 
was  occurred  in  20  and  12  minutes  for  F2  and  F3  formulation 
respectively. 
• Dissolution  profile  for  tablet  prepared  by  F4  and F5  as  formulation 
containing  8%  and  10%  of  crospovidone  as  a  superdisintegrant 
respectively. It was found that 90% drug release was occurred within 
12-14 minutes for both formulations.
• Dissolution  profile  for  tablet  prepared by F6  and F7 as  formulation 
containing  8%  and  10%  of  cros-cormellose  sodium  as  a 
superdisintegrant respectively. It was found that 95% drug release was 
occurred within 14 minutes for F6 formulation, 97% drug release  was 
occurred within 10 minutes for F7 formulation
• The stability studies of the selected formulation were studied at 40°C 
and 75 RH for one month. The drug content and physical parameters 
like hardness and disintegration time were evaluated.
In conclusion,
Now a days  inhaler are used for treating congestion due to asthma, it 
is costly and most of the patient are not satisfy that type of administration.
Mouth dissolving tablets overcome these disadvantages viz it is more 
economic  and  release  the  drug  immediately  thus  improve  the  patient 
compliance.
Dissolution  rate  increases  in  following  manner  with  increasing  the 
concentration of the superdisintegrants.Control < sodium starch glyolate < 
crospovidone< cros carmellose sodium as a superdisintegrants showed faster 
release than control  formulation and formulation prepared by other super 
disinter grants which was pivotal step in rapid disintegration and ultimately 
to quick release of drug from tablet.
Future Plan:
• Further, to determine the bioavailability of the mouth dissolving 
tablets  by  using  suitable  animal  model  and  confirm  their 
absorption of drug. 
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